Visit https://www.peervoice.com/KYP860 to view the entire programme with slides. After completing “Optimising HBV Treatment Outcomes Whilst We Hunt for a Cure”, participants will be able to: Identify the importance of reducing hepatocellular carcinoma (HCC) risk and improving secondary outcomes in patients receiving viral suppressive therapy; Recognise that antiviral suppressive therapies may differ in their impact on HCC risk and secondary outcomes; Describe the latest data for suppressive therapies and their potential impact on treatment strategies.

Optimising HBV Treatment Outcomes Whilst We Hunt for a Cure

PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

Education

Training

Language Courses

Higher Education

K-12

Educational Technology

Medicine

Science & Medicine

Science

Health & Fitness

How To

Visit https://www.peervoice.com/BSG860 to view the entire programme with slides. After completing “George Kassianos, CBE, MD (Hons), FRCGP / Gili Regev-Yochay, MD - Current 2024 COVID-19 Vaccination Campaign: The Evidence Supporting the Call to Action”, participants will be able to: Summarise the evidence supporting the need for the current 2024 COVID-19 vaccination campaign for older adults and vulnerable individuals; and Outline the key recommendations by the World Health Organization (WHO) and European Centre for Disease Prevention and Control (ECDC) on the current 2024 COVID-19 vaccination roll-out.

George Kassianos, CBE, MD (Hons), FRCGP / Gili Regev-Yochay, MD - Current 2024 COVID-19 Vaccination Campaign: The Evidence Supporting the Call to Action

Visit https://www.peervoice.com/DPR860 to view the entire programme with slides. After completing “Martin van Hagen, MD, PhD - Patients Receiving Immunoglobulin Therapy: Emerging Technology for Patient-Integrated Care”, participants will be able to: Discuss how technology has been used to optimise care of chronic diseases; Recognise the needs for simplifying the management of immunoglobulin therapy using device and digital technologies; and Identify technologies that are in development to support patient-integrated care for those requiring immunoglobulin therapy and key considerations for their implementation.

Martin van Hagen, MD, PhD - Patients Receiving Immunoglobulin Therapy: Emerging Technology for Patient-Integrated Care

Visit https://www.peervoice.com/SGG860 to view the entire programme with slides. After completing “Sharon Walmsley, CM, MSc, MD - Individualising ART as We Travel Through Time: Decisions Along a Life’s Journey”, participants will be able to: Identify patient and antiretroviral therapy (ART) characteristics that may influence decisions on which ART regimen to initiate in people with HIV at initial diagnosis; Translate the clinical data on the impact of ART on the risk of birth defects in context of current clinical recommendations for viral suppression of HIV in pregnant individuals; Use the benefits and limitations of long-acting injectable antiretroviral therapy (LAI-ART) to identify which people living with HIV may be appropriate for LAI-ART; and Explain the impact of age-related changes such as menopause and cognitive decline on the clinical management of people living with HIV.

Sharon Walmsley, CM, MSc, MD - Individualising ART as We Travel Through Time: Decisions Along a Life’s Journey

Visit https://www.peervoice.com/ERK860 to view the entire programme with slides. After completing “Jürgen Rockstroh, MD - HIV and Hepatitis B: Managing Coinfections in PLWH”, participants will be able to: Outline the latest treatment guidelines for people living with HIV (PLWH) who are coinfected with hepatitis B virus (HBV); Summarise the benefits and limitations of current therapies for HIV/HBV coinfection; and Assess the latest clinical data for HIV regimens for treatment of HIV/HBV coinfection.

Jürgen Rockstroh, MD - HIV and Hepatitis B: Managing Coinfections in PLWH

Visit https://www.peervoice.com/QDM860 to view the entire programme with slides. After completing “Antonella Castagna, MD - Designing Treatment Regimens to Suppress Multidrug-Resistant HIV: What Would You Do?”, participants will be able to: Recognise key PLWH and disease factors that need to be considered when designing an optimal treatment regimen for people with multidrug-resistant HIV; Identify current and emerging therapies for people with multidrug-resistant HIV; and Design individualised treatment regimens for people with multidrug-resistant HIV.

Optimising HBV Treatment Outcomes Whilst We Hunt for a Cure

Download our free app to listen on your phone